Cytokinetics, Incorporated (CYTK) Stock
CYTK Key Statistics
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CEO: Robert I. Blum. Company website
CYTK — Frequently Asked Questions
What is the CYTK stock price today?
Cytokinetics, Incorporated (CYTK) trades at $68.78, down 1.63% on the day, as of Sep 20, 2026 14:57 UTC.
What is Cytokinetics, Incorporated's market cap?
Cytokinetics, Incorporated has a market capitalisation of $8.56B, calculated from the live CYTK share price and shares outstanding.
What is the P/E ratio of CYTK?
CYTK has no meaningful price-to-earnings ratio: Cytokinetics, Incorporated lost $7.22 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Cytokinetics, Incorporated make?
Cytokinetics, Incorporated generated revenue of $70.96M over the trailing twelve months, which puts the stock at 120.61 times sales.
What is the 52-week range for CYTK?
CYTK has traded between $47.22 and $88.31 over the past 52 weeks, and the last price is 22.1% below that high.
Is Cytokinetics, Incorporated profitable?
No. Cytokinetics, Incorporated is loss-making, with a net margin of -1,259.87% over the trailing twelve months.
What is the analyst price target for CYTK?
Wall Street analysts rate CYTK Buy, with an average price target of $112.50, 63.6% above the current price.
What sector is Cytokinetics, Incorporated in?
Cytokinetics, Incorporated is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Cytokinetics, Incorporated?
Robert I. Blum is the chief executive of Cytokinetics, Incorporated, which employs 673 people.
Where can I track CYTK in real time?
QFI Terminal shows CYTK with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See CYTK live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CYTK in Terminal See plans